Bosh sahifaSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Yopilish kursi
1 687,40 ₹
Kunlik diapazon
1 661,10 ₹ - 1 700,00 ₹
Yillik diapazon
1 460,90 ₹ - 1 960,35 ₹
Bozor kapitalizatsiyasi
4,04 trln INR
Oʻrtacha hajm
2,91 mln
Narx/foyda
35,74
Dividend daromadliligi
0,95%
Asosiy maydon
NSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 129,59 mlrd | 8,14% |
Joriy xarajat | 75,61 mlrd | 20,16% |
Sof foyda | 21,50 mlrd | -19,01% |
Sof foyda marjasi | 16,59 | -25,10% |
Har bir ulushga tushum | 10,01 | -13,02% |
EBITDA | 34,05 mlrd | 9,13% |
Amaldagi soliq stavkasi | 33,68% | — |
Balans
Jami aktivlari
Jami passivlari
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 249,88 mlrd | 30,89% |
Jami aktivlari | 921,01 mlrd | 7,77% |
Jami passivlari | 196,15 mlrd | 6,85% |
Umumiy kapital | 724,86 mlrd | — |
Tarqatilgan aksiyalar | 2,39 mlrd | — |
Narxi/balansdagi bahosi | 5,58 | — |
Aktivlardan daromad | — | — |
Kapitaldan daromad | 9,40% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (INR) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 21,50 mlrd | -19,01% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Tashkil etilgan
1983
Bosh ofis
Sayt
Xodimlar soni
43 000
